Mayo Medical Laboratories, National Decision Support Company Team up to Develop Careselect™ Blood, a Comprehensive Approach to Patient Blood Management

Mayo Clinic implemented a patient blood-management program in 2010 on its Rochester campus and has since experienced a 35-percent reduction of blood transfusions, improving patient outcomes and achieving significant savings. Using best practices from the program, Mayo Medical Laboratories (MML) collaborated with National Decision Support Company (NDSC) to combine Mayo’s clinical knowledge with NDSC’s industry-leading expertise in electronic health record (EHR) clinical-decision support.

Together, MML and NDSC have developed a new patient blood-management solution called CareSelect Blood. The program will assist health care providers with the appropriate utilization of blood products, improving patient care, and reducing costs.

“With blood being a finite and expensive resource, we need to practice proper stewardship to prevent overuse,” says Daryl Kor, M.D., an anesthesiologist and Medical Director of Patient Blood Management at Mayo Clinic. “Current studies indicate that 40 to 60 percent of transfusions are deemed unnecessary or avoidable.”*

About CareSelect Blood

CareSelect Blood features 100 curated transfusion guidelines that are authored and maintained by Mayo Clinic. The platform leverages data from more than 740,000 individual transfusion events. These guidelines can be integrated into a health care organization’s EHR within the physician’s workflow to ensure proper ordering.

CareSelect Blood also offers consulting services. “We have subject matter experts who will visit the health care organization to provide on-site training, review analytics and reports, and discuss the evidence-based transfusion guidelines,” says Dr. Kor. “This program can be customized to a hospital’s specific needs and tailored to various personas within an organization—for example, surgery, nursing, or the laboratory.”

“The problem is this: too many transfusions, too much waste, and an increased probability of adverse outcomes,” says Michael Mardini, CEO of National Decision Support Company. “By expanding our relationship with Mayo Medical Laboratories, we’re able to reduce variation of care, provide reliable standards, and report data needed to improve performance. This can lead to improved population health, increased provider efficiency, and lower cost of care.”

Mayo Medical Laboratories and NDSC

In 2017, MML and NDSC co-developed CareSelect Lab, a decision-support platform that aggregates clinical knowledge and provides real-time test-ordering guidance to physicians, addressing common areas of test misutilization.

“Mayo Medical Laboratories and NDSC continue to find ways to improve health care for providers and their patients,” adds Mardini. “With our CareSelect Blood and CareSelect Lab solutions, we have designed programs that address many of the main concerns of health care institutions when it comes to patient care, health insurance costs, and the wasteful use of resources.”

Note: Mayo has a financial interest in the product referenced in this news release. Mayo will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

*Shander A, Fink A, Jividroozi M, et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev. 2011 Jul;25(3):232-246.e53.

gmchiri

Gina Chiri-Osmond

Gina Chiri-Osmond is a Marketing Channel Manager at Mayo Medical Laboratories. She manages public relations and media outreach. Gina has worked at Mayo Clinic since 2011. Outside of work, Gina is going for gold in volleyball at the 2020 Olympics in Tokyo . . . or at small-town summer festivals.